Literature DB >> 11333762

[Prevalence of chronic hidden infections in a cohort of patients in substitutive treatment with methadone].

J Portilla1, J Esteban, R Llinares, J Belda, J Sánchez-Payá, M Isabel Manso, G de Estudio Protocolo-INH.   

Abstract

BACKGROUND: To analyse prevalence of hidden hepatitis B infection (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and tuberculosis infection in drug users (DU) in a maintenance programme with methadone (MPM). PATIENTS AND
METHOD: 189 DU were tested for HBV, HCV, HIV and tuberculin test. Drug addition history and route of administration were evaluated.
RESULTS: Prevalence of HIV, HCV, and tuberculous infection was 29.2%, 75.9% and 59.3% respectively. Intravenous route, early use of heroin and delay to enter in MPM were significatively associated with HIV and HCV infections.
CONCLUSIONS: There is a high prevalence of tuberculous and HCV infections in DU. Early access to MPM could decrease prevalence of those infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333762     DOI: 10.1016/s0025-7753(01)71817-9

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  4 in total

1.  Tuberculosis knowledge, perceived risk and risk behaviors among homeless adults: effect of ethnicity and injection drug use.

Authors:  Adeline Nyamathi; Heather Sands; Angela Pattatucci-Aragón; Jill Berg; Barbara Leake
Journal:  J Community Health       Date:  2004-12

2.  Hepatitis C and B prevalence in Spanish prisons.

Authors:  P Saiz de la Hoya; A Marco; J García-Guerrero; A Rivera
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-28       Impact factor: 3.267

Review 3.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

4.  [Differential health and toxicological features of drug-dependents in treatment and in active consumption].

Authors:  C Navarro Cañadas; P Bachiller Luque; T Palacios Martín; P Ruiz Muñoz; M Herrero Baladrón; I Sánchez Lite
Journal:  Aten Primaria       Date:  2003-10-15       Impact factor: 1.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.